VUKOTIC, Ranka
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.563
AS - Asia 2.184
EU - Europa 1.712
SA - Sud America 269
Continente sconosciuto - Info sul continente non disponibili 72
AF - Africa 69
OC - Oceania 5
Totale 8.874
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.439
SG - Singapore 658
CN - Cina 465
PL - Polonia 324
HK - Hong Kong 309
GB - Regno Unito 298
VN - Vietnam 285
IT - Italia 259
SE - Svezia 195
BR - Brasile 189
FI - Finlandia 174
BD - Bangladesh 154
DE - Germania 102
RU - Federazione Russa 102
KR - Corea 64
CA - Canada 62
IN - India 48
BG - Bulgaria 39
UA - Ucraina 35
ES - Italia 31
FR - Francia 31
TR - Turchia 30
JP - Giappone 29
AR - Argentina 26
ID - Indonesia 26
NL - Olanda 25
ZA - Sudafrica 24
AE - Emirati Arabi Uniti 21
MX - Messico 19
IQ - Iraq 18
CZ - Repubblica Ceca 15
AT - Austria 13
CO - Colombia 13
CR - Costa Rica 12
VE - Venezuela 12
LT - Lituania 11
MA - Marocco 10
RO - Romania 10
CL - Cile 9
PH - Filippine 9
EG - Egitto 8
MY - Malesia 8
PK - Pakistan 8
DZ - Algeria 7
ET - Etiopia 7
PE - Perù 7
DO - Repubblica Dominicana 6
SA - Arabia Saudita 6
AL - Albania 5
AU - Australia 5
BE - Belgio 5
CH - Svizzera 5
GR - Grecia 5
IE - Irlanda 5
IL - Israele 5
PY - Paraguay 5
TN - Tunisia 5
UZ - Uzbekistan 5
GT - Guatemala 4
JM - Giamaica 4
JO - Giordania 4
NI - Nicaragua 4
NP - Nepal 4
PR - Porto Rico 4
QA - Qatar 4
A2 - ???statistics.table.value.countryCode.A2??? 3
EC - Ecuador 3
EE - Estonia 3
GE - Georgia 3
KH - Cambogia 3
KZ - Kazakistan 3
RS - Serbia 3
TH - Thailandia 3
UY - Uruguay 3
BO - Bolivia 2
GH - Ghana 2
HN - Honduras 2
HR - Croazia 2
IR - Iran 2
MT - Malta 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CI - Costa d'Avorio 1
CU - Cuba 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
GD - Grenada 1
HT - Haiti 1
HU - Ungheria 1
Totale 8.794
Salva come PNG Salva come JPEG
Città #
Santa Clara 561
Ashburn 531
Singapore 440
Warsaw 319
Fairfield 313
Hong Kong 305
Chandler 302
San Jose 179
Helsinki 168
Houston 161
Nyköping 157
Woodbridge 124
Council Bluffs 123
Wilmington 113
Cambridge 108
Beijing 105
Southend 104
London 101
Los Angeles 101
Seattle 98
Chicago 92
Ho Chi Minh City 89
New York 86
Hanoi 74
San Diego 55
Seoul 55
The Dalles 54
Hefei 51
Ann Arbor 49
Moscow 46
Salt Lake City 45
Dearborn 44
Princeton 41
Sofia 38
Orem 36
Buffalo 32
Jacksonville 32
Milan 31
Shanghai 31
Boardman 30
Modena 30
São Paulo 26
Tokyo 25
Dallas 23
Da Nang 20
Frankfurt am Main 20
Jakarta 20
Palma 18
Jersey City 17
Haiphong 16
Redwood City 16
Tampa 14
Brooklyn 13
Izmir 13
Vancouver 13
Brno 12
North Bergen 12
Phoenix 12
Toronto 12
Bologna 11
Elk Grove Village 11
Johannesburg 11
Wuhan 11
Baghdad 10
Belo Horizonte 10
Bremen 10
Columbus 10
Denver 10
Guangzhou 10
Montreal 10
Nanjing 10
Reading 10
Redondo Beach 10
Sterling 10
Berlin 9
Charlotte 9
Chennai 9
Falls Church 9
Grafing 9
Kilburn 9
San José 9
Augusta 8
Cairo 8
Chiswick 8
Eugene 8
Istanbul 8
Miano 8
New Delhi 8
Newark 8
Rome 8
San Francisco 8
Vienna 8
Addis Ababa 7
Amsterdam 7
Groningen 7
Lauterbourg 7
Poplar 7
Riverside 7
Secaucus 7
Stanford 7
Totale 6.117
Salva come PNG Salva come JPEG
Nome #
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 637
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis 443
ANTICOAGULANT THERAPY IS SAFE AND EFFECTIVE IN PREVENTING PORTAL VEIN THROMBOSIS (PVT) IN ADVANCED CIRRHOTIC PATIENTS: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY 408
Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C 386
ENOXAPARIN PREVENTS PORTAL VEIN THROMBOSIS (PVT) AND DECOMPENSATION IN ADVANCED CIRRHOTIC PATIENTS: FINAL REPORT OF A PROSPECTIVE RANDOMIZED CONTROLLED STUDY 343
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 331
Reproductive status is associated with the severity of fibrosis in women with hepatitis C. 304
Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study 296
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 263
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 229
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 218
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 217
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 214
Clinical and serological profile of primary biliary cirrhosis in men 209
Familial intrahepatic cholestasis: New and wide perspectives 204
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 199
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 190
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 187
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 182
De novo autoimmune hepatitis in liver transplant: State-of-the-art review 180
Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B 179
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 177
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B 176
Hepatitis C Virus Core Antigen (HCVAg): An affordable assay to monitor the efficacy of treatment in DAAs era 176
The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series 168
Bone marrow derived stem cells for the treatment of end-stage liver disease 166
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older 162
The increase of Ribavirin dose improves sustained virological response in HCV-Genotype 1 patients with a partial response to PEG-Interferon and Ribavirin. 155
Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group 153
Hepatitis B virus and immune response 151
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation 145
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study 145
Insights into cancer severity from biomolecular interaction mechanisms 145
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort 140
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 134
Impact of psychosocial status on liver transplant process 134
Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholi fatty liver disease: an Italian community-based population study 131
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 131
Hepatitis C virus eradication in the elderly: The challenge worth a long-life elixir? 127
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 119
Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options 118
Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma 102
Totale 8.874
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.513
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.513
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022638 0 0 40 40 16 51 23 87 83 77 123 98
2022/2023746 108 105 69 78 74 114 11 67 81 4 21 14
2023/2024455 21 25 27 70 102 21 43 47 5 6 21 67
2024/20251.530 47 12 4 121 353 241 67 121 171 102 118 173
2025/20263.704 188 63 165 322 535 547 406 191 389 376 319 203
2026/2027503 160 230 113 0 0 0 0 0 0 0 0 0
Totale 8.874